AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportAtomwise vs BenevolentAI
Atomwise
VS
BenevolentAI
Verdict by Category
Detailed Comparison
Feature
Atomwise
BenevolentAI
Pricing
CustomAtomwise operates through enterprise partnership and co-development agreements — there is no self-serve access or published pricing.
Collaboration types include: sponsored research agreements (pharma/biotech pays Atomwise to run AI-powered hit discovery campaigns), co-development partnerships (shared IP and milestone/royalty structures), and academic program access for universities through the ATOM initiative.
New CEO Steve Worland is also steering Atomwise toward an internal proprietary drug pipeline, which will generate revenue through future licensing and partnering deals as candidates mature into preclinical and clinical stages.
Contact Atomwise through atomwise.com for partnership and collaboration inquiries.
CustomBenevolentAI operates through enterprise pharma collaboration agreements and platform licensing — there is no self-serve access or published pricing.
Revenue models include: discovery collaborations with pharma companies (AstraZeneca, Merck) structured as multi-year agreements with upfront fees and milestones; licensing of its knowledge exploration tools as standalone software to pharma R&D organizations; and advancing its own clinical pipeline to inflection points for licensing or co-development.
Total funding raised is approximately $1.9B, with the company listed on Euronext Amsterdam (AMS: BAI). Contact BenevolentAI through benevolent.com for partnership and platform licensing inquiries.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
Deep learning for structure-based drug discovery — AtomNet screens 16B+ compounds to find hits for any disease target
Clinical-stage AI drug discovery with integrated wet labs and AstraZeneca and Merck collaborations
Atomwise Pros & Cons
Pros
- Invented deep learning for structure-based drug discovery in 2012 — true pioneer in the field
- AtomNet screens 16B+ compounds in under 2 days — fastest virtual screening at this scale
- 775+ collaborations and 250+ partners — most validated partnership network in AI drug discovery
- Tackles undruggable targets that traditional methods can't address
- Strong academic program: 40+ universities including Harvard, Stanford, and Duke
- New Foundation Model announced 2026 — next-generation AI for molecular discovery
- $226M+ raised from DCVC, Khosla, Y Combinator, Tencent, B Capital, and Baidu
Cons
- Early-stage company — no FDA-approved drugs from the platform yet
- Shifting focus from platform licensing to proprietary pipeline adds execution risk
- Smaller team (~100-250 employees) compared to larger AI drug discovery peers
- Revenue still modest at $5-25M range — pre-commercial stage
- Deep tech focus means long timelines before patient impact is realized
BenevolentAI Pros & Cons
Pros
- Fully integrated AI + wet lab model — unique among AI drug discovery platforms
- AstraZeneca and Merck partnerships validate the platform's target identification quality
- In-house wet labs in Cambridge close the loop between AI prediction and biology
- Euronext Amsterdam listed (AMS: BAI) — $1.9B raised, publicly accountable
- Phase 1 clinical data for BEN-8744 (ulcerative colitis) represents real clinical progress
- Multiple disease areas covered: oncology, rare disease, CNS, fibrosis, and immunology
- Knowledge exploration tools can be licensed separately from drug pipeline
Cons
- Listed on Euronext Amsterdam (AMS: BAI) — less accessible to US retail investors
- Clinical pipeline still in early stages — no approved drugs yet
- Smaller than competitors like Recursion in terms of funding and team size
- Revenue dependent on collaboration milestones — lumpy and uncertain
- Wet-lab operations add cost complexity vs. pure software drug discovery peers